Background: MARITIME-HF is a randomized, Phase 3, placebo-controlled, multicenter, double-blind study (sponsored by Amgen) evaluating the efficacy and safety of maridebart cafraglutide (MariTide) in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and obesity. The primary objective is to assess the effect of treatment on cardiovascular death and heart failure events. The double-blind treatment period will last approximately 3.5 years, with an optional open-label extension of up to 2 years. Type: Sponsor-initiated Trial Registraton No.: NCT07037459 https://clinicaltrials.gov/study/NCT07037459 Trial Status: Recruiting Enrolling Centers: Worldwide (multicentric) Core Study Team Basel: